Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.

[1]  J. Domecq,et al.  Antifibrinolytic therapy to reduce haemoptysis from any cause. , 2016, The Cochrane database of systematic reviews.

[2]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[3]  A. Sachdeva,et al.  Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[4]  Catherine Beigelman-Aubry,et al.  Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management , 2015, European Respiratory Journal.

[5]  H. Fung,et al.  Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[6]  S. Keshavjee,et al.  The Effectiveness of Culture-Directed Preemptive Anti-Aspergillus Treatment in Lung Transplant Recipients at One Year After Transplant , 2015, Transplantation.

[7]  W. G. Nichols,et al.  Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. , 2015, Blood.

[8]  M. Finkelman,et al.  Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis. , 2015, Medical mycology.

[9]  Marisa H Miceli,et al.  Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Couriel,et al.  Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis , 2015, Mycoses.

[11]  J. Wingard,et al.  Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Denning,et al.  Antibody testing in aspergillosis--quo vadis? , 2015, Medical mycology.

[13]  A. Bazzocchi,et al.  High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Wen,et al.  Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies , 2015, Antimicrobial Agents and Chemotherapy.

[15]  L. Joosten,et al.  IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. , 2015, The Journal of infectious diseases.

[16]  N. Mueller,et al.  PTX3 Polymorphisms and Invasive Mold Infections After Solid Organ Transplant. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  G. Ercolani,et al.  High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis in Patients Undergoing Liver Transplantation: A Prospective Phase II Trial , 2015, Transplantation.

[18]  D. Denning,et al.  Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) , 2015, The Journal of asthma : official journal of the Association for the Care of Asthma.

[19]  C. Solano,et al.  Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Wingard,et al.  Combination Antifungal Therapy for Invasive Aspergillosis , 2015, Annals of Internal Medicine.

[21]  R. Nation,et al.  Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis , 2015, Critical reviews in microbiology.

[22]  M. Cuenca‐Estrella,et al.  Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Denning,et al.  Clinical implications of interferon‐γ genetic and epigenetic variants , 2014, Immunology.

[24]  E. Scheller,et al.  Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. Porcher,et al.  Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  M. Garg,et al.  Cut‐off values of serum IgE (total and A. fumigatus ‐specific) and eosinophil count in differentiating allergic bronchopulmonary aspergillosis from asthma , 2014, Mycoses.

[27]  G. Thompson,et al.  Fungal infections of the skin and nail: new treatment options , 2014, Expert review of anti-infective therapy.

[28]  L. Delgado,et al.  Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  D. Kontoyiannis,et al.  Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity , 2014, Antimicrobial Agents and Chemotherapy.

[30]  A. McLachlan,et al.  Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. , 2014, International journal of antimicrobial agents.

[31]  G. Raponi,et al.  Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role? , 2014, Diagnostic microbiology and infectious disease.

[32]  R. Agarwal,et al.  Reversed Halo Sign: A Systematic Review , 2014, Respiratory Care.

[33]  A. Thamboo,et al.  Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence‐based review and recommendations , 2014, International forum of allergy & rhinology.

[34]  C. Collins.  Adverse health effects of marijuana use. , 2014, The New England journal of medicine.

[35]  A. Caliendo,et al.  PCR in Diagnosis of Invasive Aspergillosis: a Meta-Analysis of Diagnostic Performance , 2014, Journal of Clinical Microbiology.

[36]  A. Simpson,et al.  A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[37]  R. Feng,et al.  Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  J. Cisneros,et al.  Antifungal combination therapy for invasive aspergillosis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Perfect,et al.  Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia , 2014, Antimicrobial Agents and Chemotherapy.

[40]  A. Rosengart,et al.  Mold infections of the central nervous system. , 2014, The New England journal of medicine.

[41]  C. Tcherakian,et al.  Pulmonary arterial mycotic pseudoaneurysms in a patient with invasive pulmonary aspergillosis. Successful occlusion by coils. , 2014, American journal of respiratory and critical care medicine.

[42]  M. Cuenca‐Estrella,et al.  Antifungal Susceptibility Profile of Cryptic Species of Aspergillus , 2014, Mycopathologia.

[43]  H. Yamazaki,et al.  Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. , 2014, The Journal of infectious diseases.

[44]  D. Denning,et al.  Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis , 2014, PloS one.

[45]  Nora D Volkow,et al.  Adverse health effects of marijuana use. , 2014, The New England journal of medicine.

[46]  R. Sato,et al.  Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[47]  T. Hohl,et al.  Independent contribution of bronchoalveolar lavage and serum galactomannan in the diagnosis of invasive pulmonary aspergillosis , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[48]  M. Cuenca‐Estrella.  Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[49]  P. Verweij,et al.  Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. , 2014, The Journal of antimicrobial chemotherapy.

[50]  A. McLachlan,et al.  Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. , 2014, The Journal of antimicrobial chemotherapy.

[51]  M. Arendrup.  Update on antifungal resistance in Aspergillus and Candida. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[52]  B. Alexander,et al.  Epidemiology of Invasive Mold Infections in Lung Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[53]  R. Gilroy,et al.  Microwave ablation of a large renal aspergilloma , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[54]  P. Kirby,et al.  Fungal Infections : Review of Aspergillosis to Histoplasmosis and Everything in Between , 2014 .

[55]  M. Ali,et al.  Orbital aspergillosis in immunocompetent patients , 2014, British Journal of Ophthalmology.

[56]  O. Kwon,et al.  Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis. , 2014, The Journal of infection.

[57]  B. Moriyama,et al.  Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. , 2014, The Journal of infection.

[58]  E. Ntzani,et al.  Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. , 2014, The journal of allergy and clinical immunology. In practice.

[59]  R. Gorton,et al.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. , 2014, The Journal of antimicrobial chemotherapy.

[60]  E. Zintzaras,et al.  Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence , 2014, Pediatric pulmonology.

[61]  R. Porcher,et al.  Use and Limits of (1-3)-β-d-Glucan Assay (Fungitell), Compared to Galactomannan Determination (Platelia Aspergillus), for Diagnosis of Invasive Aspergillosis , 2014, Journal of Clinical Microbiology.

[62]  A. Wardlaw,et al.  Fungal allergy in asthma–state of the art and research needs , 2014, Clinical and Translational Allergy.

[63]  A. Caliendo,et al.  Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States , 2014, Journal of Clinical Microbiology.

[64]  A. Simpson,et al.  Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[65]  Andrew J. Nieuwkoop,et al.  Amphotericin forms an extramembranous and fungicidal sterol sponge , 2014, Nature chemical biology.

[66]  P. Pagès,et al.  The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  C. Kauffman.  Diagnosis and management of fungal urinary tract infection. , 2014, Infectious disease clinics of North America.

[68]  M. Netea,et al.  Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis , 2014, PloS one.

[69]  S. Keshavjee,et al.  Pretransplant Aspergillus Colonization of Cystic Fibrosis Patients and the Incidence of Post–Lung Transplant Invasive Aspergillosis , 2014, Transplantation.

[70]  Ming Zhang,et al.  Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies. , 2014, Journal of thoracic disease.

[71]  A. Chakrabarti,et al.  Empirical Amphotericin B therapy on Day 4 or Day 8 of Febrile Neutropenia , 2014, Mycoses.

[72]  G. Alexander.  A retrospective review comparing the treatment outcomes of emergency lung resection for massive haemoptysis with and without preoperative bronchial artery embolization. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[73]  J. Wain,et al.  Surgical therapy of pulmonary aspergillomas: a 30-year North American experience. , 2014, The Annals of thoracic surgery.

[74]  D. Denning,et al.  Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR , 2014, Mycoses.

[75]  A. Mantovani,et al.  Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. , 2014, The New England journal of medicine.

[76]  Q. Zhan,et al.  Prognostic value of serum galactomannan index in critically ill patients with chronic obstructive pulmonary disease at risk of invasive pulmonary aspergillosis , 2014, Chinese medical journal.

[77]  E. Haponik,et al.  Survey of Academic Pulmonologists, Oncologists, and Infectious Disease Physicians on the Role of Bronchoscopy in Managing Hematopoietic Stem Cell Transplantation Patients With Pulmonary Infiltrates , 2014, Journal of bronchology & interventional pulmonology.

[78]  R. Fanin,et al.  Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real‐life combo study , 2013, Mycoses.

[79]  R. Moss.  Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis , 2013, European Respiratory Journal.

[80]  D. Tacke,et al.  Aspergillosis of bones and joints – a review from 2002 until today , 2013, Mycoses.

[81]  M. Arendrup,et al.  Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. , 2013, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[82]  J. Dunning,et al.  Does tranexamic acid stop haemoptysis? , 2013, Interactive cardiovascular and thoracic surgery.

[83]  S. Park,et al.  Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population , 2013, Infection & chemotherapy.

[84]  G. Mikus,et al.  Steady-state pharmacokinetics and metabolism of voriconazole in patients. , 2013, The Journal of antimicrobial chemotherapy.

[85]  K. Mumtaz,et al.  Anti-Aspergillus Prophylaxis in Lung Transplantation: A Systematic Review and Meta-analysis , 2013, Current Infectious Disease Reports.

[86]  C. Heussel,et al.  Aspergillus PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities , 2013, Journal of Clinical Microbiology.

[87]  A. Safdar,et al.  Aerosolized Amphotericin B Lipid Complex as Adjunctive Treatment for Fungal Lung Infection in Patients with Cancer‐Related Immunosuppression and Recipients of Hematopoietic Stem Cell Transplantation , 2013, Pharmacotherapy.

[88]  T. Hohl,et al.  The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  D. Hansell,et al.  Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis , 2013, Thorax.

[90]  Nina Singh,et al.  Micafungin Versus Amphotericin B Lipid Complex for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients , 2013, Transplantation.

[91]  D. Denning,et al.  Novel immunologic classification of aspergillosis in adult cystic fibrosis. , 2013, The Journal of allergy and clinical immunology.

[92]  M. Garg,et al.  Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature , 2013, Mycoses.

[93]  F. V. van Tiel,et al.  Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  D. Denning,et al.  Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre’s experience , 2013, Journal of Cardiothoracic Surgery.

[95]  T. Link,et al.  Voriconazole-induced periostitis in two post-transplant patients. , 2013, Journal of radiology case reports.

[96]  D. Denning,et al.  Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[97]  G. M. Halmágyi,et al.  Neuro‐ophthalmology of invasive fungal sinusitis: 14 consecutive patients and a review of the literature , 2013, Clinical & experimental ophthalmology.

[98]  G. Snell,et al.  Preemptive treatment with voriconazole in lung transplant recipients , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[99]  K. Al-shair,et al.  Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. , 2013, Chest.

[100]  S. Swaminathan,et al.  Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus. , 2013, Diagnostic microbiology and infectious disease.

[101]  V. Welch,et al.  Risk‐adjusted relationship between voriconazole utilization and non‐melanoma skin cancer among lung and heart/lung transplant patients , 2013, Transplant infectious disease : an official journal of the Transplantation Society.

[102]  J. Schaenman.  Is universal antifungal prophylaxis mandatory in lung transplant patients? , 2013, Current opinion in infectious diseases.

[103]  D. Solomon,et al.  Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study , 2013, Annals of the rheumatic diseases.

[104]  A. Chakrabarti,et al.  Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies , 2013, Mycoses.

[105]  A. Rohit,et al.  Culture-Negative Aspergillus Peritonitis Diagnosed by Peritoneal Biopsy , 2013, Peritoneal Dialysis International.

[106]  S. Simpson,et al.  Association of bronchoalveolar lavage yield with chest computed tomography findings and symptoms in immunocompromised patients , 2013, Annals of thoracic medicine.

[107]  J. Mainardi,et al.  Aspergillus endocarditis in the era of new antifungals: major role for antigen detection. , 2013, The Journal of infection.

[108]  A. Petrilli,et al.  The water supply system as a potential source of fungal infection in paediatric haematopoietic stem cell units , 2013, BMC Infectious Diseases.

[109]  B. Farley,et al.  Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model , 2013, PloS one.

[110]  M. J. Buitrago,et al.  Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[111]  John Moore,et al.  Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. , 2013, The Lancet. Infectious diseases.

[112]  M. Hoenigl,et al.  Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. , 2013, Current pharmaceutical design.

[113]  Ronald N. Jones,et al.  Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance , 2013, Journal of Clinical Microbiology.

[114]  S. Teoh,et al.  Aspergillus terreus Endogenous Endophthalmitis in a Nonimmunocompromised Patient with a History of Bronchiectasis , 2013, Ocular immunology and inflammation.

[115]  C. Viscoli,et al.  (1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  T. Peláez,et al.  Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study) , 2013, Antimicrobial Agents and Chemotherapy.

[117]  G. Egerer,et al.  Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis , 2013, Mycoses.

[118]  P. Carver,et al.  The Evolving Role of Antifungal Susceptibility Testing , 2013, Pharmacotherapy.

[119]  J. Löffler,et al.  Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[120]  M. Srinivasan,et al.  The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. , 2013, JAMA ophthalmology.

[121]  D. Denning,et al.  Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[122]  R. Elashoff,et al.  Colonization With Small Conidia Aspergillus Species Is Associated With Bronchiolitis Obliterans Syndrome: A Two‐Center Validation Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[123]  Brittany E. Howard,et al.  Oral Steroid Therapy in Chronic Rhinosinusitis with and without Nasal Polyposis , 2013, Current Allergy and Asthma Reports.

[124]  M. Gershwin,et al.  Fungal Disease of the Nose and Sinuses: An Updated Overview , 2013, Current Allergy and Asthma Reports.

[125]  D. Denning,et al.  Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum , 2013, Thorax.

[126]  C. Casals,et al.  Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[127]  Nina Singh,et al.  Aspergillosis in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[128]  I. Kocyiğit,et al.  Diagnosis of Aspergillus niger Peritonitis in a Peritoneal Dialysis Patient by Peritoneal Galactomannan and β-d-Glucan Detection , 2013, Peritoneal Dialysis International.

[129]  P. Thomas,et al.  Mycotic keratitis: epidemiology, diagnosis and management. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[130]  D. Kontoyiannis,et al.  The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[131]  C. Righini,et al.  Sphenoid sinus fungus ball , 2013, European Archives of Oto-Rhino-Laryngology.

[132]  N. Pahade,et al.  Aspergillus petrous apicitis associated with cerebral and peritubular abscesses in an immunocompetent man , 2013, The Journal of Laryngology & Otology.

[133]  W. Hofmann,et al.  Diagnostic Performance of an Aspergillus-Specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis , 2013, PloS one.

[134]  D. Stevens,et al.  Experimental Evidence That Granulocyte Transfusions Are Efficacious in Treatment of Neutropenic Hosts with Pulmonary Aspergillosis , 2013, Antimicrobial Agents and Chemotherapy.

[135]  H. Koo,et al.  Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients , 2013, Pediatric blood & cancer.

[136]  J. Baddley,et al.  Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes , 2013, BMC Infectious Diseases.

[137]  Mirjam N Trame,et al.  Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis , 2013, Antimicrobial Agents and Chemotherapy.

[138]  M. Tormo,et al.  Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study). , 2013, Medical mycology.

[139]  R. Barton.  Laboratory Diagnosis of Invasive Aspergillosis: From Diagnosis to Prediction of Outcome , 2013, Scientifica.

[140]  Timothy H. Self,et al.  Update on rifampin, rifabutin, and rifapentine drug interactions , 2013, Current medical research and opinion.

[141]  J. Rello,et al.  A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. , 2012, American journal of respiratory and critical care medicine.

[142]  Charlie Strange,et al.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. , 2012, American journal of respiratory and critical care medicine.

[143]  D. Denning,et al.  Multifocal pulmonary aspergillomas: case series and review , 2012, Annals of the New York Academy of Sciences.

[144]  A. Ayadi,et al.  Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis. , 2012, Pathologie-biologie.

[145]  D. Kontoyiannis,et al.  The impact of azole resistance on aspergillosis guidelines , 2012, Annals of the New York Academy of Sciences.

[146]  D. Denning,et al.  Aspergillus bronchitis without significant immunocompromise , 2012, Annals of the New York Academy of Sciences.

[147]  M. Huynen,et al.  Discovery of a hapE Mutation That Causes Azole Resistance in Aspergillus fumigatus through Whole Genome Sequencing and Sexual Crossing , 2012, PloS one.

[148]  Kieren A Marr,et al.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. , 2012, The Journal of infection.

[149]  E. Mylonakis,et al.  Central Nervous System Aspergillosis: A Series of 14 Cases From a General Hospital and Review of 123 Cases From the Literature , 2012, Medicine.

[150]  P. G. Choe,et al.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[151]  S. Oka,et al.  A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[152]  R. Duarte,et al.  Effect of Posaconazole on Cyclosporine Blood Levels and Dose Adjustment in Allogeneic Blood and Marrow Transplant Recipients , 2012, Antimicrobial Agents and Chemotherapy.

[153]  M. Manz,et al.  Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. , 2012, Blood.

[154]  L. Leibovici,et al.  Diagnostic Accuracy of PCR Alone Compared to Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis: a Systematic Review , 2012, Journal of Clinical Microbiology.

[155]  J. Aguado,et al.  Aspergillus Tracheobronchitis: Report of 8 Cases and Review of the Literature , 2012, Medicine.

[156]  D. Kontoyiannis,et al.  Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis? , 2012, The Journal of infection.

[157]  M. Srinivasan,et al.  Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial , 2012, British Journal of Ophthalmology.

[158]  P. Jorens,et al.  Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study , 2012, Intensive Care Medicine.

[159]  A. McLachlan,et al.  Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration , 2012, Antimicrobial Agents and Chemotherapy.

[160]  N. Boyd,et al.  Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections , 2012, Antimicrobial Agents and Chemotherapy.

[161]  Suephy C. Chen,et al.  Duration of Voriconazole Exposure: An Independent Risk Factor for Skin Cancer After Lung Transplantation , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[162]  T. Buclin,et al.  Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[163]  R. Preston,et al.  A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers , 2012, The Journal of antimicrobial chemotherapy.

[164]  C. O. Kim,et al.  Diagnostic value of the serum galactomannan assay for invasive aspergillosis: It is less useful in non-haematological patients , 2012, Scandinavian journal of infectious diseases.

[165]  Y. Yau,et al.  Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. , 2012, Medical mycology.

[166]  V. Cottin,et al.  Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[167]  A. McLachlan,et al.  Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[168]  M. Gilleece,et al.  Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics , 2012, Bone Marrow Transplantation.

[169]  V. Poggi,et al.  A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy‐induced febrile neutropenia in children , 2012, British journal of haematology.

[170]  P. Boutros,et al.  Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[171]  G. Jiang,et al.  Surgical treatment for pulmonary aspergilloma: a 35-year experience in the Chinese population. , 2012, Interactive cardiovascular and thoracic surgery.

[172]  R. Arceci,et al.  Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. , 2012, Journal of the Pediatric Infectious Diseases Society.

[173]  C. Viscoli,et al.  ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients , 2012, Bone Marrow Transplantation.

[174]  W. Hope,et al.  Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections , 2012, Expert opinion on drug metabolism & toxicology.

[175]  M. Netea,et al.  Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis , 2012, Journal of Clinical Microbiology.

[176]  A. Chakrabarty,et al.  Voriconazole for fungal corneal ulcers. , 2012, Ophthalmology.

[177]  S. Koo,et al.  Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[178]  Mathias W Pletz,et al.  Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry , 2012, European Journal of Medical Research.

[179]  A. Alborzi,et al.  Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. , 2012, Journal of infection in developing countries.

[180]  V. Martín,et al.  Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT , 2012, Bone Marrow Transplantation.

[181]  M. Karlsson,et al.  Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults , 2012, Antimicrobial Agents and Chemotherapy.

[182]  D. Marriott,et al.  Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[183]  D. Denning,et al.  The Performance of Real-Time PCR, Galactomannan, and Fungal Culture in the Diagnosis of Invasive Aspergillosis in Ventilated Patients with Chronic Obstructive Pulmonary Disease (COPD) , 2012, Mycopathologia.

[184]  O. Lortholary,et al.  β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[185]  R. Porcher,et al.  The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. , 2012, Blood.

[186]  M. Hallek,et al.  Alemtuzumab for patients with chronic lymphocytic leukaemia. , 2012, The Cochrane database of systematic reviews.

[187]  J. Pilewski,et al.  Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity , 2012, Antimicrobial Agents and Chemotherapy.

[188]  C. Kibbler,et al.  From the patient to the clinical mycology laboratory: how can we optimise microscopy and culture methods for mould identification? , 2012, Journal of Clinical Pathology.

[189]  J. Loeffler,et al.  Standardization of Aspergillus PCR diagnosis , 2012, Bone Marrow Transplantation.

[190]  Andrew J Wardlaw,et al.  Fungi and allergic lower respiratory tract diseases. , 2012, The Journal of allergy and clinical immunology.

[191]  T. Peláez,et al.  Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[192]  T. Patterson,et al.  Fungal disease of the nose and paranasal sinuses. , 2012, The Journal of allergy and clinical immunology.

[193]  V. Anttila,et al.  Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[194]  I. Tleyjeh,et al.  The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[195]  K. Theunissen,et al.  Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical Validity , 2012, Journal of Clinical Microbiology.

[196]  Dieter Häussinger,et al.  Onwards and upwards: European Journal of Medical Research continues as an open access publication , 2012, European Journal of Medical Research.

[197]  Y. Hamada,et al.  Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[198]  A. Tortorano,et al.  Cross-Reactivity of Fusarium spp. in the Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay , 2011, Journal of Clinical Microbiology.

[199]  S. Magill,et al.  Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit. , 2011, The Journal of hospital infection.

[200]  H. Mansour,et al.  Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole. , 2011, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[201]  E. Grabczak,et al.  Tracheobronchial Manifestations of Aspergillus Infections , 2011, TheScientificWorldJournal.

[202]  Jaymes D. Granata,et al.  Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient. , 2011, Orthopedics.

[203]  I. Du Rand,et al.  British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults , 2011, Thorax.

[204]  S. Park,et al.  Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients , 2011, Mycoses.

[205]  D. Pappagianis,et al.  Fluoride Excess in Coccidioidomycosis Patients Receiving Long-Term Antifungal Therapy: an Assessment of Currently Available Triazoles , 2011, Antimicrobial Agents and Chemotherapy.

[206]  P. Gubbins,et al.  Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450 , 2011, Expert opinion on drug metabolism & toxicology.

[207]  F. V. van Tiel,et al.  Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009 , 2011, Emerging infectious diseases.

[208]  A. Lejay,et al.  Surgery for aspergilloma: time trend towards improved results? , 2011, Interactive cardiovascular and thoracic surgery.

[209]  B. Barlogie,et al.  Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[210]  H. Fan,et al.  Pulmonary fungal infections after bone marrow transplantation: the value of high-resolution computed tomography in predicting their etiology. , 2011, Chinese medical journal.

[211]  Yee-Chun Chen,et al.  Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan , 2011, BMC infectious diseases.

[212]  W. Melchers,et al.  Evaluation of Aspergillus PCR Protocols for Testing Serum Specimens , 2011, Journal of Clinical Microbiology.

[213]  J. Franklin,et al.  Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis , 2011, Antimicrobial Agents and Chemotherapy.

[214]  P. Batra,et al.  Oral antifungal therapy for chronic rhinosinusitis and its subtypes: a systematic review , 2011, International forum of allergy & rhinology.

[215]  A. Georgala,et al.  Inaugural bilateral aspergillus endophthalmitis in a seriously immunocompromised patient , 2011, Mycoses.

[216]  D. Denning,et al.  Peripheral neuropathy in patients on long-term triazole antifungal therapy. , 2011, The Journal of antimicrobial chemotherapy.

[217]  A. Levis,et al.  A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). , 2011, The Journal of antimicrobial chemotherapy.

[218]  T. Gumbo,et al.  Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People , 2011, Antimicrobial Agents and Chemotherapy.

[219]  G. Robson,et al.  Interrogation of Related Clinical Pan-Azole-Resistant Aspergillus fumigatus Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms in cyp51A, Upregulation of cyp51A, and Integration and Activation of Transposon Atf1 in the cyp51A Promoter , 2011, Antimicrobial Agents and Chemotherapy.

[220]  D. Kontoyiannis,et al.  Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center , 2011, Cancer.

[221]  Fiona O'Reilly Zwald,et al.  Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. , 2011, Journal of the American Academy of Dermatology.

[222]  B. Stausbøl‐Grøn,et al.  Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease , 2011, Mycoses.

[223]  R. Kaur,et al.  Voriconazole versus natamycin as primary treatment in fungal corneal ulcers , 2011, Clinical & experimental ophthalmology.

[224]  Gerd Mikus,et al.  Pharmacogenomics of the triazole antifungal agent voriconazole. , 2011, Pharmacogenomics.

[225]  M. Arendrup,et al.  A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[226]  D. Kontoyiannis,et al.  The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[227]  J. Smith,et al.  High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[228]  J. Low,et al.  Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[229]  Q. Zhan,et al.  Value of consecutive galactomannan determinations for the diagnosis and prognosis of invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease. , 2011, Medical mycology.

[230]  Z. Dvořák.  Drug-drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition. , 2011, Toxicology letters.

[231]  O. Cars,et al.  Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum Concentration , 2011, Antimicrobial Agents and Chemotherapy.

[232]  S. Stringer,et al.  Complications of allergic fungal sinusitis. , 2011, The American journal of medicine.

[233]  P. Juvvadi,et al.  Newer combination antifungal therapies for invasive aspergillosis. , 2011, Medical mycology.

[234]  J. Guarner,et al.  Histopathologic Diagnosis of Fungal Infections in the 21st Century , 2011, Clinical Microbiology Reviews.

[235]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[236]  A. Vekhoff,et al.  A retrospective series of gut aspergillosis in haematology patients. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[237]  D. Denning,et al.  Homogenisation of cystic fibrosis sputum by sonication--an essential step for Aspergillus PCR. , 2011, Journal of microbiological methods.

[238]  T. Shim,et al.  Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[239]  M. Arendrup,et al.  Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. , 2011, Medical mycology.

[240]  J. McCormack,et al.  Aspergillus endocarditis 2003-2009. , 2011, Medical mycology.

[241]  S. Ulusoy,et al.  Peritonitis Due to Aspergillus nidulans and Its Effective Treatment with Voriconazole: the First Case Report , 2011, Peritoneal Dialysis International.

[242]  D. Slain,et al.  A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. , 2011, International journal of antimicrobial agents.

[243]  W. Kremers,et al.  Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[244]  M. Kramer,et al.  Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction , 2011, Clinical transplantation.

[245]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[246]  R. Rajendran,et al.  Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity , 2011, Antimicrobial Agents and Chemotherapy.

[247]  J. Kellum,et al.  Isolation of Aspergillus in three 2009 H1N1 influenza patients , 2011, Influenza and other respiratory viruses.

[248]  G. Snell,et al.  Antifungal Prophylaxis in Lung Transplantation—A World‐wide Survey , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[249]  S. Roberts,et al.  Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[250]  J. Dipersio,et al.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.

[251]  J. Latgé,et al.  Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. , 2010, Blood.

[252]  M. Pfaller,et al.  Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles , 2010, Journal of Clinical Microbiology.

[253]  P. Ljungman,et al.  Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT , 2010, Bone Marrow Transplantation.

[254]  B. Barlogie,et al.  Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[255]  R. Amitani,et al.  Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. , 2010, The Journal of infection.

[256]  P. Lange.  Spirometric findings as predictors of survival , 2010, Thorax.

[257]  D. Sheppard,et al.  Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. , 2010, Diagnostic microbiology and infectious disease.

[258]  H. Einsele,et al.  Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study , 2010, Haematologica.

[259]  B. Esterni,et al.  Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant , 2010, Leukemia & lymphoma.

[260]  M. Arendrup,et al.  Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain , 2010, Antimicrobial Agents and Chemotherapy.

[261]  C. Marescaux,et al.  Tacrolimus-Associated Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation , 2010, European Neurology.

[262]  J. Chodakewitz,et al.  Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[263]  C. Viscoli,et al.  Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[264]  B. Damle,et al.  Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). , 2010, Journal of pharmaceutical sciences.

[265]  H. Jafri,et al.  Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children , 2010, Antimicrobial Agents and Chemotherapy.

[266]  D. Denning,et al.  Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma , 2010, European Respiratory Journal.

[267]  M. Shivaprakash,et al.  Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study , 2010, Bone Marrow Transplantation.

[268]  D. Marriott,et al.  Voriconazole concentrations and outcome of invasive fungal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[269]  B. Piraino,et al.  PERITONEAL DIALYSIS-RELATED INFECTIONS RECOMMENDATIONS: 2010 UPDATE , 2010, Peritoneal Dialysis International.

[270]  J. Turnidge,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) , 2010, Journal of Clinical Microbiology.

[271]  M. Shivaprakash,et al.  Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry , 2010, BMC infectious diseases.

[272]  Michael Boeckh,et al.  Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[273]  G. Lyman,et al.  Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[274]  L. Cuzin,et al.  Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia , 2010, Haematologica.

[275]  Hojoong Kim,et al.  Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[276]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[277]  N. Bhadelia,et al.  Invasive Aspergillosis after Pandemic (H1N1) 2009 , 2010, Emerging infectious diseases.

[278]  T. Kohno,et al.  Video-assisted thoracic surgery for pulmonary aspergilloma. , 2010, Interactive cardiovascular and thoracic surgery.

[279]  Chun-Yuan Wang,et al.  Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. , 2010, American journal of ophthalmology.

[280]  J. Solé,et al.  Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[281]  Lixin Xie,et al.  Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation. , 2010, Ophthalmology.

[282]  Thomas J Walsh,et al.  Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[283]  E. Anaissie,et al.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[284]  G. Alangaden,et al.  In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. , 2010, The Journal of antimicrobial chemotherapy.

[285]  S. Husain,et al.  Fungi and Molds following Lung Transplantation , 2010, Seminars in respiratory and critical care medicine.

[286]  A. Chakrabarti,et al.  Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India , 2010, Mycoses.

[287]  M. García-Ramírez,et al.  Management of obstructive renal failure caused by bilateral renal aspergilloma in an immunocompetent newborn. , 2010, Journal of medical microbiology.

[288]  M. Arendrup,et al.  EUCAST breakpoints for antifungals. , 2010, Drug news & perspectives.

[289]  E. Klemm,et al.  Otomycosis: Diagnosis and treatment. , 2010, Clinics in dermatology.

[290]  S. Koo,et al.  Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis , 2010, Journal of Clinical Microbiology.

[291]  S. Yousem,et al.  Impact of Mold Infections in Explanted Lungs on Outcomes of Lung Transplantation , 2010, Transplantation.

[292]  D. Holzmann,et al.  Isolated fungus ball mimicking mucocele or frontal sinus tumour: a diagnostic pitfall , 2009, The Journal of Laryngology & Otology.

[293]  M. Shivaprakash,et al.  An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. , 2009, The Journal of antimicrobial chemotherapy.

[294]  G. Verhoef,et al.  Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[295]  Min Chen,et al.  Invasive Pulmonary Aspergillosis in Patients With Antineutrophil Cytoplasmic Antibody Associated Vasculitis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[296]  D. Denning,et al.  zole-resistance in Aspergillus: Proposed nomenclature and breakpoints , 2009 .

[297]  B. Segal,et al.  Infection Control Measures to Prevent Invasive Mould Diseases in Hematopoietic Stem Cell Transplant Recipients , 2009, Mycopathologia.

[298]  S. K. Kim,et al.  Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. , 2009, The Journal of thoracic and cardiovascular surgery.

[299]  K. Sepkowitz,et al.  Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated , 2009, Bone Marrow Transplantation.

[300]  T. F. Wang,et al.  Periostitis Secondary to Prolonged Voriconazole Therapy in Lung Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[301]  D. Denning,et al.  Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[302]  D. Lebeaux,et al.  Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults , 2009, Antimicrobial Agents and Chemotherapy.

[303]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[304]  H. Einsele,et al.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. , 2009, European journal of cancer.

[305]  J. Michalek,et al.  Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and Effectiveness , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[306]  J. Baddley,et al.  Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network , 2009, Journal of Clinical Microbiology.

[307]  M. Schell,et al.  Voriconazole Provides Effective Prophylaxis for Invasive Fungal Infection in Patients Receiving Glucocorticoid Therapy for Graft-Versus-Host Disease , 2009, Bone Marrow Transplantation.

[308]  I. T. Ten Berge,et al.  Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. , 2009, Medical mycology.

[309]  D. Denning,et al.  Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.

[310]  T. Franquet,et al.  Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis. , 2009, European journal of radiology.

[311]  M. Yigla,et al.  Radiological findings of early invasive pulmonary aspergillosis in immune‐compromised patients , 2009, Hematological oncology.

[312]  O. Lortholary,et al.  In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes , 2009, Antimicrobial Agents and Chemotherapy.

[313]  J. Kosterink,et al.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[314]  P. Wormald,et al.  The Role of Itraconazole in Recalcitrant Fungal Sinusitis , 2009, American journal of rhinology & allergy.

[315]  G. Ubeaud‐Séquier,et al.  Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. , 2009, Current drug metabolism.

[316]  Dirk Roos,et al.  Chronic Granulomatous Disease: The European Experience , 2009, PloS one.

[317]  A. Vekhoff,et al.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[318]  H. Einsele,et al.  A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT , 2009, Bone Marrow Transplantation.

[319]  Nilo A. Avila,et al.  Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis , 2009, Antimicrobial Agents and Chemotherapy.

[320]  A. Sangoi,et al.  Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution. , 2009, American journal of clinical pathology.

[321]  N. Wiederhold.  Paradoxical echinocandin activity: a limited in vitro phenomenon? , 2009, Medical mycology.

[322]  D. Denning,et al.  Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[323]  J. Rowinska.  UPDATE ON FUNGAL PERITONITIS AND ITS TREATMENT , 2009 .

[324]  F. Morell,et al.  Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[325]  J. Matuszkiewicz-Rowińska.  Update on Fungal Peritonitis and its Treatment , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[326]  P. Martín-Dávila,et al.  False-Positive Results of Aspergillus Galactomannan Antigenemia in Liver Transplant Recipients , 2009, Transplantation.

[327]  G. Verhoef,et al.  Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients , 2009, Cancer.

[328]  P. Herman,et al.  Antifungal Therapy of Aspergillus Invasive Otitis Externa: Efficacy of Voriconazole and Review , 2008, Antimicrobial Agents and Chemotherapy.

[329]  Mats O. Karlsson,et al.  Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.

[330]  K. Genoway,et al.  Effectiveness of itraconazole in the management of refractory allergic fungal rhinosinusitis. , 2008, Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale.

[331]  J. Wingard,et al.  Combination antifungal therapy: From bench to bedside , 2008, Current infectious disease reports.

[332]  D. Kontoyiannis,et al.  Utility of Galactomannan Enzyme Immunoassay and (1,3) β-d-Glucan in Diagnosis of Invasive Fungal Infections: Low Sensitivity for Aspergillus fumigatus Infection in Hematologic Malignancy Patients , 2008, Journal of Clinical Microbiology.

[333]  W. Melchers,et al.  Academic Editor: Chris Kibbler, Royal Free Hospital London, United Kingdom , 2007 .

[334]  A. Pastor,et al.  Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. , 2008, Transplantation proceedings.

[335]  A. Solé.  Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. , 2008, International journal of antimicrobial agents.

[336]  M. Joannidis,et al.  Levels of amphotericin B lipid formulations in ascites. , 2008, The Journal of antimicrobial chemotherapy.

[337]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[338]  L. Zhao,et al.  Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. , 2008, The New England journal of medicine.

[339]  Nina Singh,et al.  Performance Characteristics of the Platelia Aspergillus Enzyme Immunoassay for Detection of Aspergillus Galactomannan Antigen in Bronchoalveolar Lavage Fluid , 2008, Clinical and Vaccine Immunology.

[340]  Subcommittee on Antifungal Susceptibility Testing.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[341]  S. Pounds,et al.  Galactomannan Antigenemia in Pediatric Oncology Patients With Invasive Aspergillosis , 2008, The Pediatric infectious disease journal.

[342]  K. Iatrou,et al.  Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes. , 2008, International angiology : a journal of the International Union of Angiology.

[343]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[344]  M. Truong,et al.  Reversed halo sign in invasive pulmonary fungal infections. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[345]  A. Zaas,et al.  Plasminogen Alleles Influence Susceptibility to Invasive Aspergillosis , 2008, PLoS genetics.

[346]  E. Mellado,et al.  Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus , 2008, Antimicrobial Agents and Chemotherapy.

[347]  B. Barlogie,et al.  Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[348]  W. Hop,et al.  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[349]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[350]  E. Rosenberg,et al.  Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation. , 2008, The New England journal of medicine.

[351]  S. Daniel,et al.  Ototopical antifungals and otomycosis: a review. , 2008, International journal of pediatric otorhinolaryngology.

[352]  D. Kontoyiannis,et al.  Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy , 2008, Cancer.

[353]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[354]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[355]  S. de Botton,et al.  Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies , 2007, Cancer.

[356]  P. Gubbins.  Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients , 2007, Current opinion in infectious diseases.

[357]  D. Kontoyiannis,et al.  Caspofungin as Primary Antifungal Prophylaxis in Stem Cell Transplant Recipients , 2007, Pharmacotherapy.

[358]  G. Papanicolaou,et al.  Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[359]  E. Kleinerman,et al.  Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis , 2007, Antimicrobial Agents and Chemotherapy.

[360]  J. Ragnaud,et al.  Drug–drug interactions with systemic antifungals in clinical practice , 2007, Pharmacoepidemiology and drug safety.

[361]  D. Kontoyiannis,et al.  Random plasma concentrations of voriconazole decline over time. , 2007, The Journal of infection.

[362]  L. Vélez,et al.  Diagnostic accuracy of bronchoalveolar lavage samples in immunosuppressed patients with suspected pneumonia: analysis of a protocol. , 2007, Respiratory medicine.

[363]  S. Pileri,et al.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.

[364]  R. Baughman.  Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. , 2007, Seminars in respiratory and critical care medicine.

[365]  N. Milman,et al.  Aspergillus infection in lung transplant patients: incidence and prognosis , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[366]  L. Gordon,et al.  Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.

[367]  S. Tong,et al.  Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[368]  G. Lyman,et al.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[369]  J. Perfect,et al.  Prospective Aspergillus Galactomannan Antigen Testing in Pediatric Hematopoietic Stem Cell Transplant Recipients , 2007, The Pediatric infectious disease journal.

[370]  A. Deykin,et al.  Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[371]  G. Margueritte,et al.  Inherited long QT syndrome revealed by antifungals drug–drug interaction , 2007, Journal of clinical pharmacy and therapeutics.

[372]  M. Robiony,et al.  Surgical treatment of Aspergillus mycetomas of the maxillary sinus: review of the literature. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[373]  P. Bartolomeo,et al.  Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection , 2007, Bone Marrow Transplantation.

[374]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[375]  J. Donnelly,et al.  Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[376]  P. V. D. van der Voort,et al.  Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. , 2007, The Journal of antimicrobial chemotherapy.

[377]  A. Gabelmann,et al.  Relevant imaging findings of cerebral aspergillosis on MRI: a retrospective case‐based study in immunocompromised patients , 2007, European journal of neurology.

[378]  H. Nunes,et al.  Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. , 2007, Chest.

[379]  D. Hillaire‐buys,et al.  Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database , 2007, The Annals of pharmacotherapy.

[380]  R. Pozzi-mucelli,et al.  Comparison of CT Features of Aspergillus and Bacterial Pneumonia in Severely Neutropenic Patients , 2007, Journal of thoracic imaging.

[381]  W. Melchers,et al.  Multiple-triazole-resistant aspergillosis. , 2007, The New England journal of medicine.

[382]  W. Melchers,et al.  A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations , 2007, Antimicrobial Agents and Chemotherapy.

[383]  P. Grosjean,et al.  Fungus balls of the paranasal sinuses: a review , 2007, European Archives of Oto-Rhino-Laryngology.

[384]  Raoul Herbrecht,et al.  Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[385]  J. Perfect,et al.  Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[386]  M. Kramer,et al.  Outbreak of aspergillosis infections among lung transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[387]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[388]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[389]  K. Koike,et al.  A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid , 2007, Scandinavian journal of infectious diseases.

[390]  A. Glasmacher,et al.  Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis , 2006, Cancer.

[391]  L. Wheat,et al.  Plasmalyte as a Cause of False-Positive Results for Aspergillus Galactomannan in Bronchoalveolar Lavage Fluid , 2006, Journal of Clinical Microbiology.

[392]  K. Sepkowitz,et al.  Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[393]  D. Pakstis,et al.  Voriconazole Prophylaxis in Lung Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[394]  D. Pittet,et al.  Primary Invasive Aspergillosis of the Digestive Tract: Report of Two Cases and Review of the Literature , 2006, Infection.

[395]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[396]  H. Einsele,et al.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati , 2006, Blood.

[397]  P. Verweij,et al.  The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. , 2006, International journal of antimicrobial agents.

[398]  N. J. Coker,et al.  Otomycosis: Clinical features and treatment implications , 2006, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[399]  D. Denning,et al.  Multi-azole resistance in Aspergillus fumigatus. , 2006, International journal of antimicrobial agents.

[400]  T. Walsh,et al.  Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. , 2006, The Journal of infectious diseases.

[401]  A. Demir,et al.  Analysis of Surgical Treatment for Pulmonary Aspergilloma , 2006, Asian Cardiovascular and Thoracic Annals.

[402]  S. Chanock,et al.  Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy , 2006, Clinical Microbiology Reviews.

[403]  M. Finkelman,et al.  Reactivity of (1→3)-β-d-Glucan Assay with Commonly Used Intravenous Antimicrobials , 2006, Antimicrobial Agents and Chemotherapy.

[404]  P. Corr.  Management of Severe Hemoptysis from Pulmonary Aspergilloma Using Endovascular Embolization , 2006, CardioVascular and Interventional Radiology.

[405]  A. Webster,et al.  Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[406]  T. Gildea,et al.  Endobronchial Fungal Disease: An Under-Recognized Entity , 2006, Respiration.

[407]  D. Kontoyiannis,et al.  Fungal osteoarticular infections in patients treated at a comprehensive cancer centre: a 10-year retrospective review. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[408]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[409]  E. Kerem,et al.  Aspergillus bronchitis in cystic fibrosis. , 2006, Chest.

[410]  J. Donnelly,et al.  Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder , 2006, Annals of Hematology.

[411]  D. Kontoyiannis,et al.  Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[412]  I. Hassan,et al.  Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature. , 2006, The Journal of infection.

[413]  E. Anaissie,et al.  Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients , 2006, Antimicrobial Agents and Chemotherapy.

[414]  F. Locatelli,et al.  Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. , 2006, Transplantation proceedings.

[415]  P. Lugtenburg,et al.  Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. , 2006, The Journal of antimicrobial chemotherapy.

[416]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[417]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[418]  Dean F Sittig,et al.  Reducing warfarin medication interactions: an interrupted time series evaluation. , 2006, Archives of internal medicine.

[419]  D. Denning,et al.  Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis , 2006, Journal of Infection.

[420]  D. Denning,et al.  The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. , 2006, The Journal of infection.

[421]  T. Patterson,et al.  Sequential or Combination Antifungal Therapy with Voriconazole and Liposomal Amphotericin B in a Guinea Pig Model of Invasive Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.

[422]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[423]  G. Klintmalm,et al.  Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: A Prospective, Multicenter, Observational Study , 2006, Transplantation.

[424]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[425]  D. Benjamin,et al.  Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections , 2006, Antimicrobial Agents and Chemotherapy.

[426]  D. Stevens,et al.  Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. , 2006, Medical mycology.

[427]  D. Kontoyiannis,et al.  Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection , 2006, Antimicrobial Agents and Chemotherapy.

[428]  Z. Sajjad,et al.  Diagnostic MR imaging features of craniocerebral Aspergillosis of sino-nasal origin in immunocompetent patients , 2006, Acta Neurochirurgica.

[429]  E. Estey,et al.  Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.

[430]  M. Kramer,et al.  Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[431]  A. Baruch,et al.  Safety and Pharmacokinetics of Coadministered Voriconazole and Anidulafungin , 2005, Journal of clinical pharmacology.

[432]  A. Shad,et al.  Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents , 2005, Antimicrobial Agents and Chemotherapy.

[433]  J. Ito,et al.  Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA) , 2005, Bone Marrow Transplantation.

[434]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[435]  E. Thiel,et al.  Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.

[436]  A. Gratwohl,et al.  Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[437]  M. Falagas,et al.  Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials , 2005, British journal of haematology.

[438]  P. Pitisuttithum,et al.  Activity of posaconazole in the treatment of central nervous system fungal infections. , 2005, The Journal of antimicrobial chemotherapy.

[439]  D. Denning,et al.  Laboratory diagnosis of invasive aspergillosis. , 2005, The Lancet. Infectious diseases.

[440]  J. Bennett.  Salvage therapy for aspergillosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[441]  B. Alexander,et al.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[442]  E. Sionov,et al.  Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. , 2005, The Journal of antimicrobial chemotherapy.

[443]  O. Velazquez,et al.  Successful treatment of Aspergillus prosthetic valve endocarditis with oral voriconazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[444]  A. Shad,et al.  Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients , 2005, Antimicrobial Agents and Chemotherapy.

[445]  M. García-Fernández,et al.  Aspergillus Endocarditis , 2005, Echocardiography.

[446]  F. Gavini,et al.  Bifidobacterial Lipoglycan as a New Cause for False-Positive Platelia Aspergillus Enzyme-Linked Immunosorbent Assay Reactivity , 2005, Journal of Clinical Microbiology.

[447]  P. Muñoz,et al.  Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[448]  D. Kontoyiannis,et al.  Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[449]  A. Glasmacher,et al.  Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[450]  S. Holland,et al.  Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[451]  F. Lescure,et al.  Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[452]  D. Kontoyiannis,et al.  The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic stem cell transplantation , 2005 .

[453]  Nina Singh,et al.  Aspergillus Infections in Transplant Recipients , 2005, Clinical Microbiology Reviews.

[454]  J. Pontón,et al.  Contribution of (1→3)-β-d-Glucan Chromogenic Assay to Diagnosis and Therapeutic Monitoring of Invasive Aspergillosis in Neutropenic Adult Patients: a Comparison with Serial Screening for Circulating Galactomannan , 2005, Journal of Clinical Microbiology.

[455]  M. Ghannoum,et al.  Combination Treatment of Invasive Fungal Infections , 2005, Clinical Microbiology Reviews.

[456]  W. Leisenring,et al.  Aspergillus Galactomannan Enzyme Immunoassay and Quantitative PCR for Diagnosis of Invasive Aspergillosis with Bronchoalveolar Lavage Fluid , 2004, Journal of Clinical Microbiology.

[457]  D. Denning,et al.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[458]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[459]  B. Keevil,et al.  Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[460]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[461]  M. Boeckh,et al.  Combination antifungal therapy for invasive aspergillosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[462]  J. Szer,et al.  A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[463]  L. Bartelt,et al.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[464]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[465]  A. Webster,et al.  Antifungal agents for preventing fungal infections in solid organ transplant recipients. , 2004, The Cochrane database of systematic reviews.

[466]  E. Estey,et al.  β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome , 2004 .

[467]  R. Storb,et al.  Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[468]  E. Mellado,et al.  Substitutions at Methionine 220 in the 14α-Sterol Demethylase (Cyp51A) of Aspergillus fumigatus Are Responsible for Resistance In Vitro to Azole Antifungal Drugs , 2004, Antimicrobial Agents and Chemotherapy.

[469]  Russell E. Lewis,et al.  Toward more effective antifungal therapy: the prospects of combination therapy , 2004, British journal of haematology.

[470]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[471]  J. Donnelly,et al.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. , 2004, The Lancet. Infectious diseases.

[472]  Nina Singh,et al.  Prospective Assessment of Platelia™Aspergillus Galactomannan Antigen for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[473]  C. Cordonnier,et al.  Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients , 2004, Bone Marrow Transplantation.

[474]  J. Heitman,et al.  In Vitro Interactions between Antifungals and Immunosuppressants against Aspergillus fumigatus , 2004, Antimicrobial Agents and Chemotherapy.

[475]  M. Desco,et al.  Risk Factors of Invasive Aspergillosis after Heart Transplantation: Protective Role of Oral Itraconazole Prophylaxis , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[476]  J. Perfect,et al.  Combination Antifungal Therapy , 2004, Antimicrobial Agents and Chemotherapy.

[477]  W. Leisenring,et al.  Cyclophosphamide metabolism is affected by azole antifungals. , 2004, Blood.

[478]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[479]  J. Perfect,et al.  Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients , 2004, Transplantation.

[480]  H. O. D. Camp,et al.  Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection , 2004, The Lancet.

[481]  Nina Singh,et al.  Efficacy of Galactomannan Antigen in the Platelia Aspergillus Enzyme Immunoassay for Diagnosis of Invasive Aspergillosis in Liver Transplant Recipients , 2004, Journal of Clinical Microbiology.

[482]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[483]  A. Sulahian,et al.  False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. , 2003, The New England journal of medicine.

[484]  E. Sionov,et al.  Polyene and cytokine treatment of experimental aspergillosis. , 2003, FEMS immunology and medical microbiology.

[485]  N. Wood,et al.  Voriconazole potentiates warfarin-induced prothrombin time prolongation. , 2003, British journal of clinical pharmacology.

[486]  R. Soiffer,et al.  Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. , 2003, Blood.

[487]  D. Denning.  Echinocandin antifungal drugs , 2003, The Lancet.

[488]  D. Denning,et al.  Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[489]  David W Bates,et al.  Clinical impact of drug-drug interactions with systemic azole antifungals. , 2003, Drugs of today.

[490]  D. Denning,et al.  Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[491]  R. López-martínez,et al.  Fungal peritonitis in 15 patients on continuous ambulatory peritoneal dialysis (CAPD) , 2003, Mycoses.

[492]  J. Meis,et al.  Molecular Epidemiology of Aspergillus fumigatus Isolates Recovered from Water, Air, and Patients Shows Two Clusters of Genetically Distinct Strains , 2003, Journal of Clinical Microbiology.

[493]  Russell E. Lewis,et al.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.

[494]  T. Walsh,et al.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. , 2003, The Journal of infectious diseases.

[495]  D. Denning,et al.  Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[496]  M. Lichterfeld,et al.  Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. , 2003, American journal of clinical pathology.

[497]  L. D. Nelson,et al.  Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[498]  T. Korman,et al.  Management of Aspergillus Osteomyelitis: Report of Failure of Liposomal Amphotericin B and Response to Voriconazole in an Immunocompetent Host and Literature Review , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[499]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[500]  H. Hoogsteden,et al.  Galactomannan detection in computerized tomography‐based broncho‐alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis , 2003, British journal of haematology.

[501]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[502]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[503]  N. Paphitou,et al.  Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. , 2003, Diagnostic microbiology and infectious disease.

[504]  G. Goldman,et al.  Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole , 2003, Antimicrobial Agents and Chemotherapy.

[505]  D. Denning,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Microbiology Standards of Care British Society for Medical Mycology Proposed Standards of Care for Patients with Invasive Fungal Infections , 2022 .

[506]  John H Rex,et al.  Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. , 2003, Blood.

[507]  R. Cornwell,et al.  Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. , 2003, Chest.

[508]  Nina Singh,et al.  Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[509]  E. Mellado,et al.  A Point Mutation in the 14α-Sterol Demethylase Gene cyp51A Contributes to Itraconazole Resistance in Aspergillus fumigatus , 2003, Antimicrobial Agents and Chemotherapy.

[510]  K. Sepkowitz,et al.  Refractory Aspergillus pneumonia in patients with acute leukemia , 2003, Cancer.

[511]  A. Warris,et al.  Multidrug resistance in Aspergillus fumigatus. , 2002, The New England journal of medicine.

[512]  J. Latgé,et al.  Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. , 2002, Blood.

[513]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[514]  J. Verschakelen,et al.  Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. , 2002, The Journal of infectious diseases.

[515]  Michael Boeckh,et al.  Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors , 2002, Transfusion.

[516]  H. Moch,et al.  Late Aspergillus fumigatus endomyocarditis with brain abscess as a lethal complication after heart transplantation. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[517]  E. Anaissie,et al.  Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[518]  Russell E. Lewis,et al.  Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary Aspergillosis , 2002, Antimicrobial Agents and Chemotherapy.

[519]  Theresa Hahn,et al.  Efficacy of High-Efficiency Particulate Air Filtration in Preventing Aspergillosis in Immunocompromised Patients With Hematologic Malignancies , 2002, Infection Control & Hospital Epidemiology.

[520]  J. Wingard,et al.  A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[521]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[522]  T. Patterson,et al.  Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis , 2002, Antimicrobial Agents and Chemotherapy.

[523]  D. Denning,et al.  Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. , 2002, Fungal genetics and biology : FG & B.

[524]  B. Lebeau,et al.  Prevention of nosocomial fungal infection: the French approach. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[525]  W. Hellinger,et al.  Primary bilateral parenchymal renal Aspergillus infection. , 2002, Urology.

[526]  E. Bow,et al.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.

[527]  S. Erdman,et al.  Aspergillus cholangitis: A late complication after Kasai portoenterostomy. , 2002, Journal of pediatric surgery.

[528]  A. Soubani,et al.  The clinical spectrum of pulmonary aspergillosis. , 2002, Chest.

[529]  L. Ekelund,et al.  Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. , 2002, Acta radiologica.

[530]  C. Viscoli,et al.  Aspergillus Galactomannan Antigen in the Cerebrospinal Fluid of Bone Marrow Transplant Recipients with Probable Cerebral Aspergillosis , 2002, Journal of Clinical Microbiology.

[531]  J. Bergerat,et al.  Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[532]  H. Lazarus,et al.  Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.

[533]  E. Anaissie,et al.  Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[534]  A. Stanson,et al.  Bronchial artery embolization : experience with 54 patients. , 2002, Chest.

[535]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[536]  T. Yoshiura,et al.  Imaging findings in intracranial aspergillosis. , 2002, Academic radiology.

[537]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[538]  E. Wang,et al.  Interaction of Common Azole Antifungals with P Glycoprotein , 2002, Antimicrobial Agents and Chemotherapy.

[539]  E. Brummer,et al.  In vivo GM‐CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages , 2001, Journal of leukocyte biology.

[540]  D. Stevens,et al.  Intrathecal amphotericin in the management of coccidioidal meningitis. , 2001, Seminars in respiratory infections.

[541]  S. Chanock,et al.  Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[542]  R. Hajjeh,et al.  Counterpoint: invasive aspergillosis and the environment--rethinking our approach to prevention. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[543]  A. Schwarer,et al.  Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy , 2001, Annals of Internal Medicine.

[544]  J. Perfect,et al.  SAFETY OF AEROSOLIZED AMPHOTERICIN B LIPID COMPLEX IN LUNG TRANSPLANT RECIPIENTS12 , 2001, Transplantation.

[545]  J. Cleary,et al.  Intravenous Itraconazole , 2001, The Annals of pharmacotherapy.

[546]  L. Willems,et al.  Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics , 2001, Journal of clinical pharmacy and therapeutics.

[547]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[548]  G. Leverger,et al.  Efficacy of Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in Immunosuppressed Paediatric Patients , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[549]  H. El-Solh,et al.  ENHANCED VINCRISTINE NEUROTOXICITY FROM DRUG INTERACTIONS: Case Report and Review of Literature , 2001, Pediatric hematology and oncology.

[550]  I. Velasco,et al.  Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy. , 2000, Chest.

[551]  J. Curfs,et al.  Failure To Detect Circulating Aspergillus Markers in a Patient with Chronic Granulomatous Disease and Invasive Aspergillosis , 2000, Journal of Clinical Microbiology.

[552]  D. Hibbett,et al.  Phylogenetic species recognition and species concepts in fungi. , 2000, Fungal genetics and biology : FG & B.

[553]  P. Linden,et al.  Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid‐organ transplant recipients with invasive fungal infections , 2000 .

[554]  J. Harousseau,et al.  Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B , 2000, Antimicrobial Agents and Chemotherapy.

[555]  D. Cosgrove,et al.  Aspergillus Valve Endocarditis in Patients without Prior Cardiac Surgery , 2000, Medicine.

[556]  M. Boeckh,et al.  Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. , 2000, Blood.

[557]  Richard B. Johnston,et al.  Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.

[558]  A. Degraff,et al.  A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. , 2000, The New England journal of medicine.

[559]  M. Nucci,et al.  A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[560]  D. Greenblatt,et al.  Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.

[561]  S. Andreas,et al.  Diagnosis of pulmonary aspergillosis using optical brighteners. , 2000, The European respiratory journal.

[562]  A. Streifel,et al.  Refinements of Environmental Assessment During an Outbreak Investigation of Invasive Aspergillosis in a Leukemia and Bone Marrow Transplant Unit , 2000, Infection Control & Hospital Epidemiology.

[563]  D. Denning,et al.  SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2000, Pediatric hematology and oncology.

[564]  D. Paterson,et al.  Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF , 1999, Thorax.

[565]  Toshiyuki Yamamoto,et al.  Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery. , 1999, Internal medicine.

[566]  R. Baughman,et al.  Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. , 1999, The European respiratory journal.

[567]  A. Prentice,et al.  A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies , 1999 .

[568]  F. Diaz,et al.  Spinal aspergillus osteomyelitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[569]  R. Finberg,et al.  Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia , 1999 .

[570]  Nina Singh,et al.  Invasive aspergillosis in transplant recipients. , 1999, Medicine.

[571]  E. Wagar,et al.  Critical Evaluation of 4-Week Incubation for Fungal Cultures: Is the Fourth Week Useful? , 1998, Journal of Clinical Microbiology.

[572]  J. Chan,et al.  Pharmacokinetic Drug Interactions of Vinca Alkaloids: Summary of Case Reports , 1998, Pharmacotherapy.

[573]  R. Keenan,et al.  Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. , 1998, Chest.

[574]  T. Walsh.  Primary cutaneous aspergillosis--an emerging infection among immunocompromised patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[575]  S. Holland,et al.  Aspergillus nidulans Infection in Chronic Granulomatous Disease , 1998, Medicine.

[576]  J. Rich,et al.  Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. , 1998, Chest.

[577]  P. Kvale,et al.  Risk Factors and Outcomes Associated With Identification of Aspergillus in Respiratory Specimens From Persons With HIV Disease , 1998 .

[578]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[579]  D. De Bacquer,et al.  Impact of previous aspergillosis on the outcome of bone marrow transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[580]  J. Timsit,et al.  Aspergillus pericarditis with tamponade: report of a successfully treated case and review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[581]  J. Tillement,et al.  Systemic Antifungal Agents , 1998, Drug safety.

[582]  K. Savik,et al.  Aspergillus airway colonization and invasive disease after lung transplantation. , 1997, Chest.

[583]  Nina Singh,et al.  Invasive aspergillosis in liver transplant recipients in the 1990s. , 1997, Transplantation.

[584]  D. Snydman,et al.  The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. , 1997, The American journal of medicine.

[585]  C. Cordonnier,et al.  Fatal primary cutaneous aspergillosis in a bone marrow transplant recipient: nosocomial acquisition in a laminar-air flow room. , 1997, The Journal of hospital infection.

[586]  J. Dipersio,et al.  Resolution of invasive central nervous system aspergillosis in a transplant recipient , 1997, Bone Marrow Transplantation.

[587]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[588]  E. Jantunen,et al.  Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients , 1997, Bone Marrow Transplantation.

[589]  M. Martín,et al.  Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs , 1997, Antimicrobial agents and chemotherapy.

[590]  A. Lanti,et al.  Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: A single center experience from 1980 to 1995 , 1996, Infection.

[591]  E. Roilides,et al.  Primary cutaneous aspergillosis in neonates: case report and review. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[592]  J. Maurer,et al.  Aspergillus infection in single and double lung transplant recipients. , 1996, Transplantation.

[593]  M. Boeckh,et al.  Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[594]  E. Bryce,et al.  An outbreak of cutaneous aspergillosis in a tertiary-care hospital. , 1996 .

[595]  J. Emond,et al.  Incidence and significance of Aspergillus cultures following liver and kidney transplantation. , 1996, Transplantation.

[596]  R. Gupta,et al.  Renal aspergilloma due to Aspergillus flavus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[597]  D. Denning,et al.  Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. , 1995, Archives of internal medicine.

[598]  M. Haller,et al.  Risk factors for systemic fungal infections in liver transplant recipients , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[599]  J. Rosenfeld,et al.  Invasive Central Nervous System Aspergillosis , 1995 .

[600]  N. Giddings,et al.  Invasive otitis externa due to Aspergillus species: case report and review. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[601]  M. Langer,et al.  Invasive Pulmonary Aspergillosis: MRI, CT, and Plain Radiographic Findings and Their Contribution for Early Diagnosis , 1994 .

[602]  M. Samore,et al.  Risk factors for invasive fungal infections complicating orthotopic liver transplantation. , 1994, The Journal of infectious diseases.

[603]  A. Schaffner,et al.  Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism , 1993, Mycoses.

[604]  H. Shih,et al.  Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. , 1993, The American journal of medicine.

[605]  C. Kemper,et al.  Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[606]  J. Loyd,et al.  Infection in the transplanted and native lung after single lung transplantation. , 1993, Chest.

[607]  J. Chander,et al.  Evaluation of Calcofluor staining in the diagnosis of fungal corneal ulcer , 1993, Mycoses.

[608]  R Storb,et al.  The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. , 1993, Blood.

[609]  G. Rosner,et al.  Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. , 1992, The Journal of infectious diseases.

[610]  S. Steinberg,et al.  Patterns of Infection in Patients with Aplastic Anemia and the Emergence of Aspergillus As a Major Cause of Death , 1992, Medicine.

[611]  M. Gottlieb,et al.  Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. , 1991, The American journal of medicine.

[612]  M. Kramer,et al.  Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. , 1991, The American review of respiratory disease.

[613]  D. Denning,et al.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. , 1990, Reviews of infectious diseases.

[614]  J. Graybill,et al.  Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[615]  J. Remy,et al.  Control of hemoptysis: systemic angiography and anastomoses of the internal mammary artery. , 1988, Radiology.

[616]  K. Citron,et al.  Intrathoracic aspergilloma: role of CT in diagnosis and treatment. , 1987, Radiology.

[617]  R. Jones,et al.  Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. , 1986, The Journal of pediatrics.

[618]  A. Schaffner,et al.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. , 1985, The Journal of infectious diseases.

[619]  B. Strom,et al.  Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. , 1984, Annals of internal medicine.

[620]  D. Snover,et al.  Aspergillosis in 25 Renal Transplant Patients: Epidemiology, Clinical Presentation, Diagnosis, and Management , 1983, Annals of surgery.

[621]  P. Pizzo,et al.  Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. , 1981, The New England journal of medicine.

[622]  D. Frank,et al.  Cyclodextrin nephrosis in the rat. , 1976, The American journal of pathology.

[623]  V. Devita,et al.  Aspergillosis. The spectrum of the disease in 98 patients. , 1970, Medicine.

[624]  R. Agarwal,et al.  Role of inhaled amphotericin in allergic bronchopulmonary aspergillosis. , 2014, Journal of postgraduate medicine.

[625]  Chang Chen,et al.  Video-assisted thoracic surgery for pulmonary aspergilloma: a safe and effective procedure. , 2014, The Annals of thoracic surgery.

[626]  K. Hazen,et al.  Diagnostic accuracy of histopathologic and cytopathologic examination of Aspergillus species. , 2013, American journal of clinical pathology.

[627]  D. Falci,et al.  Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections , 2013 .

[628]  Jinny Park,et al.  The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observa , 2013, Annals of Hematology.

[629]  J. Armitage,et al.  Myeloid growth factors. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[630]  T. Walsh,et al.  Newer Systemic Antifungal Agents , 2012, Drugs.

[631]  G. Rossi,et al.  Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study , 2011, Bone Marrow Transplantation.

[632]  D. Stevens,et al.  Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[633]  G. Papanicolaou,et al.  Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[634]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[635]  D. Denning,et al.  Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. , 2009 .

[636]  C. Cordonnier,et al.  Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[637]  D. Kuypers.  Immunotherapy in Elderly Transplant Recipients , 2009, Drugs & aging.

[638]  A. Wilmer,et al.  Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. , 2008, American journal of respiratory and critical care medicine.

[639]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[640]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[641]  M. Finkelman,et al.  Reactivity of (1-->3)-beta-d-glucan assay with commonly used intravenous antimicrobials. , 2006, Antimicrobial agents and chemotherapy.

[642]  D. Denning,et al.  The invasive and saprophytic syndromes due to Aspergillus spp. , 2005, Medical mycology.

[643]  R. Niven,et al.  Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. , 2005, Respiratory medicine.

[644]  Z. Wan,et al.  Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. , 2005, The Journal of antimicrobial chemotherapy.

[645]  Y. Lien,et al.  Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[646]  D. Kontoyiannis,et al.  The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. , 2005, Cancer.

[647]  E. Estey,et al.  Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[648]  A. Wilmer,et al.  Invasive aspergillosis in critically ill patients without malignancy. , 2004, American journal of respiratory and critical care medicine.

[649]  G. Juliusson,et al.  Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. , 2003, Blood.

[650]  A. Bernard,et al.  Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[651]  M E Ellis,et al.  Fungal endocarditis: evidence in the world literature, 1965-1995. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[652]  H. Prentice,et al.  A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. , 1999, British journal of haematology.

[653]  S. Kohno,et al.  Effect of sequential combination of amphotericin B and azole antifungal agents against Aspergillus fumigatus , 1999, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[654]  R. Finberg,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, The New England journal of medicine.

[655]  P. Kvale,et al.  Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. , 1998, Chest.

[656]  A. Bernard,et al.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[657]  M. Wallace,et al.  Cutaneous aspergillosis. , 1997, Cutis.

[658]  F. Oppenheimer,et al.  Study of kidney rejection following simultaneous kidney-pancreas transplantation. , 1996, Nephron.

[659]  R. V. van Oostenbrugge,et al.  Spinal epidural abscess due to Aspergillus infection of the vertebrae: report of 3 cases. , 1996, The Netherlands journal of medicine.

[660]  M. Samore,et al.  Fungal infections complicating orthotopic liver transplantation. , 1995, Transactions of the American Clinical and Climatological Association.

[661]  R. Yeates,et al.  Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. , 1994, Drugs under experimental and clinical research.

[662]  John I. Gallin,et al.  A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. , 1991, The New England journal of medicine.

[663]  F. Meunier.  Empirical antifungal therapy in febrile granulocytopenic patients , 1989 .

[664]  Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. , 1989, The American journal of medicine.

[665]  F. Witebsky,et al.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.

[666]  B. Bulkley,et al.  Aspergillus pericarditis: Clinical and pathologic features in the immunocompromised patient , 1982, Cancer.

[667]  L. Young,et al.  Aspergillosis complicating neoplastic disease. , 1973, The American journal of medicine.